| 39.36 0.35 (0.9%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 47.07 | 1-year : | 48.23 |
| Resists | First : | 40.3 | Second : | 41.29 |
| Pivot price | 39.33  |
|||
| Supports | First : | 38.68 | Second : | 32.19 |
| MAs | MA(5) : | 39.3 |
MA(20) : | 39.51 |
| MA(100) : | 38.76 |
MA(250) : | 34.56 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 34.3 |
D(3) : | 38.8 |
| RSI | RSI(14): 43.7 |
|||
| 52-week | High : | 42.43 | Low : | 25.17 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SRDX ] has closed below upper band by 48.2%. Bollinger Bands are 73.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 60 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 39.4 - 39.59 | 39.59 - 39.79 |
| Low: | 38.52 - 38.72 | 38.72 - 38.93 |
| Close: | 39.03 - 39.36 | 39.36 - 39.68 |
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The IVD segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Mon, 09 Sep 2024
Trium Capital LLP Takes $1.41 Million Position in Surmodics, Inc. (NASDAQ:SRDX) - MarketBeat
Fri, 06 Sep 2024
SurModics (SRDX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Thu, 05 Sep 2024
Down -5.46% in 4 Weeks, Here's Why SurModics (SRDX) Looks Ripe for a Turnaround - Nasdaq
Thu, 05 Sep 2024
Wolverine Asset Management LLC Buys Shares of 25,966 Surmodics, Inc. (NASDAQ:SRDX) - MarketBeat
Tue, 13 Aug 2024
Surmodics stock on watch post FTC second request (NASDAQ:SRDX) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 14 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 3.8 (%) |
| Held by Institutions | 94.3 (%) |
| Shares Short | 430 (K) |
| Shares Short P.Month | 732 (K) |
| EPS | -0.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.27 |
| Profit Margin | -1.2 % |
| Operating Margin | -17.8 % |
| Return on Assets (ttm) | -2.6 % |
| Return on Equity (ttm) | -1.3 % |
| Qtrly Rev. Growth | -42.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 8.46 |
| EBITDA (p.s.) | 0.08 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -437.34 |
| PEG Ratio | -7 |
| Price to Book value | 4.75 |
| Price to Sales | 4.64 |
| Price to Cash Flow | -260.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|